SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Julong Holding Ltd. engages in the business of investment holding activities. It provides intelligent integrated solutions to public utilities, enterprises, commercial, and multifamily properties. The company was founded by Jia Qi Hu on August 07, 2023 and is headquartered in Beijing, China.

Julong Holding Ltd. - Ordinary Shares - Class A

Julong Holding Ltd. is experiencing extreme volatility and intense community speculation, fueled by its status as a low-float China-based stock that has seen massive percentage gains. The community is sharply divided between retail bulls anticipating a continued short squeeze and skeptics raising concerns about the company's financial transparency and the sustainability of its rapid price swings.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is currently experiencing significant market volatility and heavy selling pressure, sparking intense debate among investors over its depressed valuation versus potential structural concerns. The community remains deeply divided, with some actively accumulating shares and highlighting robust free cash flow, while others are frustrated by consistent underperformance and calls for aggressive management changes or a strategic acquisition.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is rallying strongly on news of an aggressive AI compute expansion and the development of custom internal chips to reduce long-term costs. The community is buzzing with intense bullish sentiment and active options trading, though some investors remain cautious about the massive capital expenditure and ongoing regulatory scrutiny in Europe.

Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. Its lead product includes FB-401, which is a live biotherapeutic for the treatment of inflammatory skin disease, including pediatric and adult patients with atopic dermatitis. The company was founded by Paul A. Wagner on May 3, 2017 and is headquartered in Dallas, TX.

Forte Biosciences Inc

Forte Biosciences is trending due to significant investor interest following an oversubscribed private placement of $53 million to support the clinical development of its autoimmune therapy, FB102. The community is actively discussing the stock's parabolic price action and low-float dynamics, with traders closely monitoring for potential short squeeze opportunities and ongoing volatility.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending as investors debate its transition into an agentic AI orchestration layer, with community sentiment split between those viewing its high short interest and cash-rich balance sheet as a squeeze catalyst and skeptics focused on persistent price stagnation. Despite the division, bulls are actively accumulating shares on dips, pointing to recent GAAP profitability and management's ongoing buyback program as evidence of long-term fundamental strength.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is currently a focal point for investors as they weigh the company's massive new 25 billion dollar financing framework with Brookfield against recent short-seller reports raising supply chain concerns. While some in the community view the dip as a prime buying opportunity given the scale of the deal and long-term demand for AI infrastructure, others remain skeptical about valuation and the potential for regulatory or supply-related friction.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is currently trending as investors anticipate the Phase 3 IZAR-1 trial results, which are expected to confirm the drug's best-in-class efficacy for psoriatic arthritis and potentially trigger a bidding war among major pharmaceutical acquirers. Community discussion is heavily focused on the stock's recent capital raise as a de-risking move that bolsters the company's valuation and independence ahead of a rumored multi-billion dollar buyout.

Core Scientific, Inc. engages in the business of operating a purpose-built facility for digital asset mining and provision of blockchain infrastructure, software solutions, and services. It operates under the Mining and Hosting segments. The Mining segment focuses on bitcoin mining for the company's own account. The Hosting segment includes blockchain infrastructure and third-party hosting business. The company was founded by Michael Jeffrey Levitt and Darin Feinstein on December 13, 2017 and is headquartered in Dover, DE.

Core Scientific Inc - Ordinary Shares - New

Core Scientific Inc

Core Scientific is trending as investors closely monitor its transition from a Bitcoin miner to an AI and HPC infrastructure operator, with the market awaiting further clarity on potential new anchor tenants and site energization timelines. Community discussion is heavily focused on the company's capital deployment strategy, recent financing moves, and technical consolidation as participants weigh the stock's long-term utility-focused narrative against persistent short-term volatility.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ai is currently a focal point for institutional investors, with high-profile firms like BlackRock, JPMorgan, and Goldman Sachs significantly increasing their positions despite recent revenue concerns. The community is actively debating a potential short squeeze due to high short interest, while some investors remain skeptical about fundamental growth, setting up a volatile environment ahead of upcoming earnings.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as investors react to Greenland's growing strategic importance in global rare earth supply chains, though sentiment remains divided between those anticipating long-term value from the Tanbreez project and others concerned by management's communication and delays. The community is actively debating the significance of potential US and Japanese involvement in Arctic resource development, alongside skepticism regarding the company's timeline and operational milestones.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$ELTP $PFE $JNJ $MRNA $GME  
This is why ELTP is going to be the biggest stock of 2027. 
Its all about SequestOx... Here is the info. Look it up. 
Why SequestOx is Great 
Addresses the Opioid Crisis: With opioid addiction being a major public health issue, SequestOx offers a safer alternative for patients who need strong pain relief but are at risk of misuse or abuse. 
Effective Pain Relief: The oxycodone component ensures that patients receive immediate and effective relief from moderate to severe pain, improving quality of life. 
Innovative Abuse-Deterrent Design: The sequestered naltrexone technology is a significant advancement in pharmaceutical formulations, combining efficacy with safety. 
Regulatory Progress: SequestOx has been under development with regulatory filings and pivotal bioequivalence studies underway, highlighting ELTP’s commitment to bringing this important medication to market.

Doug

$BA $BAC $TSLA $SPACX 
This company is the next big thing.  
Check them out ELTP is going to go crazy...  
Their Drug technology is the biggest and newest thing I have ever seen.  
RFK is going to make it happen for them.

StockTwits Web

$GME  
This is the Next Big Idea From Roaring Kitty.

Elite Pharmaceuticals, Inc.

Pfizer Inc

Johnson & Johnson

Moderna Inc

GameStop Corp

  
This is why ELTP is going to be the biggest stock of 2027. 
Its all about SequestOx... Here is the info. Look it up. 
Why SequestOx is Great 
Addresses the Opioid Crisis: With opioid addiction being a major public health issue, SequestOx offers a safer alternative for patients who need strong pain relief but are at risk of misuse or abuse. 
Effective Pain Relief: The oxycodone component ensures that patients receive immediate and effective relief from moderate to severe pain, improving quality of life. 
Innovative Abuse-Deterrent Design: The sequestered naltrexone technology is a significant advancement in pharmaceutical formulations, combining efficacy with safety. 
Regulatory Progress: SequestOx has been under development with regulatory filings and pivotal bioequivalence studies underway, highlighting ELTP’s commitment to bringing this important medication to market.